Please use this identifier to cite or link to this item:
http://acervodigital.unesp.br/handle/11449/71995
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Reddy, K. Rajender | - |
dc.contributor.author | Shiffman, Mitchell L. | - |
dc.contributor.author | Rodrigueztorres, Maribel | - |
dc.contributor.author | Cheinquer, Hugo | - |
dc.contributor.author | Abdurakhmanov, Djamal | - |
dc.contributor.author | Bakulin, Igor | - |
dc.contributor.author | Morozov, Viacheslav | - |
dc.contributor.author | Silva, Giovanni Faria | - |
dc.contributor.author | Geyvandova, Natalia | - |
dc.contributor.author | Stanciu, Carol | - |
dc.contributor.author | Rabbia, Michael | - |
dc.contributor.author | McKenna, Michael | - |
dc.contributor.author | Thommes, James A. | - |
dc.contributor.author | Harrison, Stephen A. | - |
dc.date.accessioned | 2014-05-27T11:24:51Z | - |
dc.date.accessioned | 2016-10-25T18:30:27Z | - |
dc.date.available | 2014-05-27T11:24:51Z | - |
dc.date.available | 2016-10-25T18:30:27Z | - |
dc.date.issued | 2010-12-01 | - |
dc.identifier | http://dx.doi.org/10.1053/j.gastro.2010.08.051 | - |
dc.identifier.citation | Gastroenterology, v. 139, n. 6, p. 1972-1983, 2010. | - |
dc.identifier.issn | 0016-5085 | - |
dc.identifier.uri | http://hdl.handle.net/11449/71995 | - |
dc.identifier.uri | http://acervodigital.unesp.br/handle/11449/71995 | - |
dc.description.abstract | Background & Aims Patients infected with hepatitis C virus (HCV) genotype 1, body weight <85 kg, and high baseline viral load respond poorly to standard doses of pegylated interferon (peginterferon) and ribavirin. We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin. Methods This double-blind randomized trial included HCV genotype 1-infected outpatients from hepatology clinics with body weight <85 kg and HCV RNA titer <400,000 IU/mL. Patients were randomized to 180 μg/wk peginterferon alfa-2a for 48 weeks plus 1200 mg/day ribavirin (standard of care) (group A, n = 191) or 1400/1600 mg/day ribavirin (group B, n = 189). Additional groups included 360 μg/wk peginterferon alfa-2a for 12 weeks then 180 μg/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day ribavirin (group C, n = 382) or 1400/1600 mg/day ribavirin (group D, n = 383). Follow-up lasted 24 weeks after treatment. Results Sustained virologic response rates (HCV RNA level <15 IU/mL at end of follow-up) in groups A, B, C, and D were 38%, 43%, 44%, and 41%, respectively. There were no significant differences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds ratio [OR], 1.08; 95% confidence interval [CI], 0.831.39; P = .584) or pooled ribavirin regimens (A + C vs B + D: OR, 1.00; 95% CI, 0.791.28; P = .974). Conclusions In patients infected with HCV genotype 1 who are difficult to treat (high viral load, body weight <85 kg), a 12-week induction regimen of peginterferon alfa-2a and/or higher-dose ribavirin is not more effective than the standard regimen. © 2010 AGA Institute. | en |
dc.format.extent | 1972-1983 | - |
dc.language.iso | eng | - |
dc.source | Scopus | - |
dc.subject | Chronic Hepatitis C | - |
dc.subject | Steatosis and Response to HCV Therapy | - |
dc.subject | Tolerability of High-Dose Pegylated Interferon | - |
dc.subject | Tolerability of High-Dose Ribavirin | - |
dc.subject | colony stimulating factor | - |
dc.subject | peginterferon alpha2a | - |
dc.subject | ribavirin | - |
dc.subject | virus RNA | - |
dc.subject | adult | - |
dc.subject | alopecia | - |
dc.subject | anemia | - |
dc.subject | arthralgia | - |
dc.subject | asthenia | - |
dc.subject | body weight | - |
dc.subject | chill | - |
dc.subject | clinical trial | - |
dc.subject | controlled clinical trial | - |
dc.subject | controlled study | - |
dc.subject | coughing | - |
dc.subject | decreased appetite | - |
dc.subject | depression | - |
dc.subject | diarrhea | - |
dc.subject | dizziness | - |
dc.subject | double blind procedure | - |
dc.subject | drug dose reduction | - |
dc.subject | drug efficacy | - |
dc.subject | drug eruption | - |
dc.subject | drug fever | - |
dc.subject | drug induced headache | - |
dc.subject | drug megadose | - |
dc.subject | drug withdrawal | - |
dc.subject | fatigue | - |
dc.subject | female | - |
dc.subject | follow up | - |
dc.subject | genotype | - |
dc.subject | hemoglobin blood level | - |
dc.subject | hepatitis C | - |
dc.subject | human | - |
dc.subject | insomnia | - |
dc.subject | irritability | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | mediastinum disease | - |
dc.subject | multicenter study | - |
dc.subject | myalgia | - |
dc.subject | nausea | - |
dc.subject | neutrophil count | - |
dc.subject | outpatient | - |
dc.subject | pneumonia | - |
dc.subject | priority journal | - |
dc.subject | pruritus | - |
dc.subject | randomized controlled trial | - |
dc.subject | respiratory tract disease | - |
dc.subject | side effect | - |
dc.subject | thorax disease | - |
dc.subject | thrombocyte count | - |
dc.subject | treatment duration | - |
dc.subject | virus load | - |
dc.subject | Adult | - |
dc.subject | Antiviral Agents | - |
dc.subject | Body Weight | - |
dc.subject | Dose-Response Relationship, Drug | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Fatty Liver | - |
dc.subject | Female | - |
dc.subject | Genotype | - |
dc.subject | Hepacivirus | - |
dc.subject | Hepatitis C, Chronic | - |
dc.subject | Humans | - |
dc.subject | Interferon Alfa-2a | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Obesity | - |
dc.subject | Polyethylene Glycols | - |
dc.subject | Ribavirin | - |
dc.subject | Viral Load | - |
dc.title | Induction pegylated interferon Alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads | en |
dc.type | outro | - |
dc.contributor.institution | University of Pennsylvania | - |
dc.contributor.institution | Bon Secours Health System | - |
dc.contributor.institution | Fundacion de Investigacion de Diego Santurce | - |
dc.contributor.institution | Hospital de Clinicas de Porto Alegre | - |
dc.contributor.institution | Moscow Medical Academy | - |
dc.contributor.institution | Gastroenterology Department | - |
dc.contributor.institution | Ministry of Defense of the Russian Federation | - |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | - |
dc.contributor.institution | No. 1 Stavropol State Medical Academy | - |
dc.contributor.institution | Gastroenterology and Hepatology Institute | - |
dc.contributor.institution | Roche | - |
dc.contributor.institution | Brooke Army Medical Center | - |
dc.description.affiliation | Division of Gastroenterology University of Pennsylvania, Philadelphia, PA | - |
dc.description.affiliation | Liver Institute of Virginia Bon Secours Health System, Newport News, VA | - |
dc.description.affiliation | Fundacion de Investigacion de Diego Santurce, Santurce | - |
dc.description.affiliation | Hospital de Clinicas de Porto Alegre, Porto Alegre | - |
dc.description.affiliation | Moscow Medical Academy, Moscow | - |
dc.description.affiliation | Gastroenterology Department, Samara | - |
dc.description.affiliation | State Postgraduate Medical Institute Ministry of Defense of the Russian Federation, Moscow | - |
dc.description.affiliation | Botucatu School of Medicine, Botucatu | - |
dc.description.affiliation | No. 1 Stavropol State Medical Academy, Stavropol | - |
dc.description.affiliation | Gastroenterology and Hepatology Institute, Iasi | - |
dc.description.affiliation | Roche, Nutley, NJ | - |
dc.description.affiliation | Roche, Welwyn | - |
dc.description.affiliation | Brooke Army Medical Center, Houston, TX | - |
dc.identifier.doi | 10.1053/j.gastro.2010.08.051 | - |
dc.rights.accessRights | Acesso restrito | - |
dc.relation.ispartof | Gastroenterology | - |
dc.identifier.scopus | 2-s2.0-78649715862 | - |
Appears in Collections: | Artigos, TCCs, Teses e Dissertações da Unesp |
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.